ARTICLE | Clinical News
TroVax: Development discontinued
May 4, 2009 7:00 AM UTC
sanofi-aventis discontinued development of TroVax due to a reprioritization of its R&D portfolio and returned rights to Oxford BioMedica. Last year, an independent DSMB said TroVax would not meet the ...